Premium
Flutroline in the Treatment of the Schizophrenic Patient
Author(s) -
KURLAND ALBERT A.,
NAGARAJU ARRAMRAJU,
HANLON THOMAS E.
Publication year - 1982
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/j.1552-4604.1982.tb02633.x
Subject(s) - psychopathology , dose , context (archaeology) , antipsychotic , psychiatry , medicine , antipsychotic drug , schizophrenia (object oriented programming) , incidence (geometry) , clinical trial , paleontology , physics , optics , biology
As an introduction into a clinical study of one of a new group of compounds having neuroleptic potential, the background and characteristics of the gamma carbolines, particularly flutroline, are cited in the general context of a review of the use of antipsychotic drugs in psychiatry. In the four‐week double‐blind trial involving dosages of 1, 5, 10, 20 and 100 mg, 48 hospitalized schizophrenic patients were given the tryptoline derivative flutroline on a once‐a‐day basis. Outcome criteria obtained weekly, including the incidence of side effects, standardized psychiatric ratings, and clinical global impressions of psychopathology, indicated that flutroline was a safe and effective antipsychotic drug. Data suggested that dosages of 20 mg and above offered the best potential for optimal clinical effectiveness.